Dennis Klinman

Dennis Klinman is a MD/PhD with extensive experience in preclinical and clinical study design, regulatory affairs, and intellectual property issues. Dennis is the discoverer of CpG oligonucleotides (TLR9 agonists) used as immune modifiers in FDA-approved vaccines and for cancer therapy. Dennis began their career in 1989 as Section Chief at the Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (FDA). In 2007, they became a Senior Investigator at the National Cancer Institute. From 2019 to 2021, they worked as a Consultant, and is currently the Chief Scientific Officer at Cobro Ventures, Inc.

Dennis Klinman obtained a Bachelor of Science in Biology, General from Saint Joseph's University from 1972 to 1976. Dennis then attended the University of Pennsylvania School of Medicine from 1976 to 1982, earning a joint MD/PhD in Medicine.